NY-MSCI
MSCI (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that its enhanced net-zero greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). MSCI is proud to be in the first group of companies to receive approval for its net-zero targets from SBTi, a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science.
Henry Fernandez, Chairman and Chief Executive Officer at MSCI, said: “Preventing the worst impacts of a warming climate demands urgent action and will require concerted action across all industries. I am pleased to announce our new commitments on the heels of the tremendous momentum that emerged from COP27. As a public company that provides net-zero investment tools and has called on capital markets participants to support decarbonization, we strive to be transparent about our own emissions and impact. MSCI’s enhanced commitments will help us drive accountability and stay aligned with a sustainable climate pathway.”
Tia Counts, Chief Responsibility and Chief Diversity Officer at MSCI, said: “In 2021, we reduced absolute Scope 1 and 2 GHG emissions by 75% and our Scope 3 GHG emissions also declined. While our trajectory for GHG emissions reduction will not be fully linear and will evolve over time to align with the latest science, technology and data, we will ensure transparent reporting of our progress, including against the enhanced targets that we are excited to announce today.”
MSCI’s Net-Zero Transition & Commitments
MSCI has reaffirmed its commitment to reach net-zero GHG emissions across the value chain by 2040 and has enhanced its science-based near-term, long-term and net-zero GHG emissions reduction targets, which have been approved by the SBTi.
MSCI has enhanced its science-based targets in the following ways:
- Accelerated the timeline for reducing absolute Scope 1, 2 and 3 GHG emissions from 2035 to 2030
- Enhanced near-term (i.e., 2030) targets to reduce absolute Scope 1 and 2 GHG emissions 80% and to reduce absolute Scope 3 GHG emissions 50%, compared to prior targets of 50% and 20%, respectively
- Committed to long-term targets to reduce absolute scope 1, 2 and 3 GHG emissions 90% by 2040
The above near and long-term targets align with a 1.5°C trajectory. All percentage reductions referenced are from a 2019 base year.
In order to meet its enhanced near and long-term targets, MCSI also announced the following new milestones for 2025:
- Reach 100% renewable electricity
- Reduce absolute Scope 1 and 2 GHG emissions by 60%
- Increase to 60% its suppliers by spend that have science-based targets, from 36% today
Today’s announcement underscores MSCI’s long-standing commitment to climate action and complements its role as a founding member of the Net Zero Financial Service Providers Alliance, which unites leading index providers, credit rating agencies, research and data providers, accounting firms, financial exchanges and other suppliers of market infrastructure in aligning with a 1.5°C pathway.
Further information about MSCI’s initiatives to reduce its overall environmental impact can be found in our Climate Transition Plan. Further information related to MSCI’s efforts to further integrate sustainability considerations into our operations can be found in our most recent CDP questionnaire and Taskforce on Climate Related Finance Disclosures (TCFD) Report.
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding corporate responsibility and climate-related plans and goals. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are detailed in MSCI’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. MSCI does not undertake to update any forward-looking statements. The inclusion of information in this press release regarding climate opportunities and risks should not be construed as a characterization regarding the materiality or financial impact of that information with respect to MSCI. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005296/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 08:00:00 CET | Press release
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 01:00:00 CET | Press release
Venture Global’s fourth long-term contract with a Japanese company7.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade o
Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 00:08:00 CET | Press release
New research quantifies the massive conversion lift from optimizing native app and web experiences, providing a critical no-code path for retailers to drive profitability Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who do
Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 17:30:00 CET | Press release
Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer
Pure Lithium Receives Saudi Patent for Vertically Integrated Lithium Metal Battery Technology25.11.2025 14:20:00 CET | Press release
Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the Kingdom of Saudi Arabia has granted the company a foundational patent titled “Vertically Integrated Pure Lithium Metal Production and Lithium Battery Production.” This broad patent covers technology that combines lithium extraction, anode production and battery manufacturing. Pure Lithium’s Brine to Battery™ is a registered trademark in the Kingdom of Saudi Arabia, planting a strong base of intellectual property in the region. “The technology is particularly relevant to Saudi Arabia because it is one of the places in the world with lithium-containing brines, and even has an abundance of vanadium, which is used in our second-generation battery,” said Founder, Chairman and CEO Emilie Bodoin. “In order to displace today’s lithium-ion battery, our vision is to create global battery hubs with closed loop supply chains, not just in the U.S., but in the many places in the world whe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
